Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 12376 | 846 | 26.2 | 52% |
Classes in level above (level 2) |
| ID, lev. above |
Publications | Label for level above |
|---|---|---|
| 3080 | 1890 | ANTISECRETORY FACTOR//LOTEPREDNOL ETABONATE//METADOXINE |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | DIFFUSION CELL EXPERIMENTS | Author keyword | 15 | 77% | 1% | 10 |
| 2 | TRANSFORMED POTTS GUY EQUATION | Author keyword | 11 | 100% | 1% | 6 |
| 3 | ROBERTS SLOAN EQUATION | Author keyword | 9 | 67% | 1% | 8 |
| 4 | DERMAL PRODRUG | Author keyword | 8 | 100% | 1% | 5 |
| 5 | CAS 4394 00 7 | Author keyword | 6 | 100% | 0% | 4 |
| 6 | NANAOCAM | Author keyword | 6 | 100% | 0% | 4 |
| 7 | ULCEROGENICITY | Author keyword | 5 | 25% | 2% | 19 |
| 8 | LIPID SOLUBILITY | Author keyword | 5 | 35% | 1% | 12 |
| 9 | AMIDE PRODRUGS | Author keyword | 4 | 67% | 0% | 4 |
| 10 | ACETYLSALICYLIC ACID MALTOL ESTER | Author keyword | 4 | 75% | 0% | 3 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | DIFFUSION CELL EXPERIMENTS | 15 | 77% | 1% | 10 | Search DIFFUSION+CELL+EXPERIMENTS | Search DIFFUSION+CELL+EXPERIMENTS |
| 2 | TRANSFORMED POTTS GUY EQUATION | 11 | 100% | 1% | 6 | Search TRANSFORMED+POTTS+GUY+EQUATION | Search TRANSFORMED+POTTS+GUY+EQUATION |
| 3 | ROBERTS SLOAN EQUATION | 9 | 67% | 1% | 8 | Search ROBERTS+SLOAN+EQUATION | Search ROBERTS+SLOAN+EQUATION |
| 4 | DERMAL PRODRUG | 8 | 100% | 1% | 5 | Search DERMAL+PRODRUG | Search DERMAL+PRODRUG |
| 5 | CAS 4394 00 7 | 6 | 100% | 0% | 4 | Search CAS+4394+00+7 | Search CAS+4394+00+7 |
| 6 | NANAOCAM | 6 | 100% | 0% | 4 | Search NANAOCAM | Search NANAOCAM |
| 7 | ULCEROGENICITY | 5 | 25% | 2% | 19 | Search ULCEROGENICITY | Search ULCEROGENICITY |
| 8 | LIPID SOLUBILITY | 5 | 35% | 1% | 12 | Search LIPID+SOLUBILITY | Search LIPID+SOLUBILITY |
| 9 | AMIDE PRODRUGS | 4 | 67% | 0% | 4 | Search AMIDE+PRODRUGS | Search AMIDE+PRODRUGS |
| 10 | ACETYLSALICYLIC ACID MALTOL ESTER | 4 | 75% | 0% | 3 | Search ACETYLSALICYLIC+ACID+MALTOL+ESTER | Search ACETYLSALICYLIC+ACID+MALTOL+ESTER |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | ACRYLIC TYPE POLYMERS | 26 | 100% | 1% | 11 |
| 2 | DERMAL PRODRUGS | 18 | 61% | 2% | 19 |
| 3 | AMIDE PRODRUGS | 11 | 100% | 1% | 6 |
| 4 | N ACYLOXYALKOXYCARBONYL DERIVATIVES | 10 | 73% | 1% | 8 |
| 5 | DIGLYCERIDE PRODRUG | 9 | 83% | 1% | 5 |
| 6 | DRUG PROTECTING GROUP | 7 | 64% | 1% | 7 |
| 7 | PHENYTOIN PRODRUGS | 7 | 57% | 1% | 8 |
| 8 | AMINOBUTYRIC ACID ESTERS | 7 | 67% | 1% | 6 |
| 9 | 1 ALKYLAZACYCLOALKAN 2 ONE ESTERS | 6 | 80% | 0% | 4 |
| 10 | ASPIRIN TRIGLYCERIDES | 6 | 80% | 0% | 4 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references | % act. ref. to same field |
|---|---|---|---|---|
| Prodrug strategies to overcome poor water solubility | 2007 | 162 | 95 | 29% |
| Prodrug Designing of NSAIDs | 2009 | 23 | 97 | 46% |
| Medication Management of Cardiac Allograft Vasculopathy After Heart Transplantation | 2015 | 1 | 10 | 40% |
| Prodrugs: design and clinical applications | 2008 | 291 | 136 | 11% |
| Amino acids as promoieties in prodrug design and development | 2013 | 10 | 90 | 21% |
| Prodrug Strategies for Enhancing the Percutaneous Absorption of Drugs | 2014 | 1 | 54 | 39% |
| Prodrug Design to Improve Pharmacokinetic and Drug Delivery Properties: Challenges to the Discovery Scientists | 2010 | 33 | 113 | 19% |
| Prodrugs: A challenge for the drug development | 2013 | 17 | 73 | 10% |
| Improved oral drug delivery: Solubility limitations overcome by the use of prodrugs | 1996 | 74 | 39 | 26% |
| Lipophilic prodrugs designed for intestinal lymphatic transport | 1996 | 54 | 48 | 29% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | UGC ADV STUDY UGC CAS PHARMACEUT SCI | 2 | 67% | 0.2% | 2 |
| 2 | CECF | 2 | 15% | 1.3% | 11 |
| 3 | IST ANALIT FARMACEUT | 1 | 50% | 0.2% | 2 |
| 4 | HIGUCHI BIOSCI DRUG DELIVERY | 1 | 50% | 0.1% | 1 |
| 5 | NINGXIA ENGN HUI MED MODERNIZAT | 1 | 50% | 0.1% | 1 |
| 6 | SCITABRIZ BRANCH | 1 | 50% | 0.1% | 1 |
| 7 | UGC ADV STUDY UGC CAS CHEM | 1 | 50% | 0.1% | 1 |
| 8 | USTAV CHEM LEC | 1 | 50% | 0.1% | 1 |
| 9 | BIOCON BRISTOL MYERS SQUIBB DEV BBRC | 0 | 33% | 0.1% | 1 |
| 10 | SRI RAMACHANDRA PHARM | 0 | 15% | 0.2% | 2 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000237012 | L DOPA PRODRUGS//6 HYDROXYDOPAMINE 6 OHDA LESIONED RAT//PROXIMAGEN NEUROSCI PLC |
| 2 | 0.0000135004 | PROXIMITY ORIENTATION//CYCLIC PRODRUG//ESTERASE SENSITIVE PRODRUGS |
| 3 | 0.0000130090 | QUIM FARMACEUT ORGAN//BENZODIOXEPINS//IN VIVO ANTITUMOUR ACTIVITY |
| 4 | 0.0000104431 | LOTEPREDNOL ETABONATE//ANTEDRUG//CHEMICAL DELIVERY SYSTEM |
| 5 | 0.0000096503 | ACEMETACIN//ACEMETACINE//CYCLOOXYGENASE 2 SELECTIVE |
| 6 | 0.0000095485 | N ACYLSULFONAMIDE//BENZOTRIAZOLE METHODOLOGY//HETEROCYCL CPDS |
| 7 | 0.0000093908 | NO ASPIRIN//NITROASPIRIN//NCX 4016 |
| 8 | 0.0000075803 | PERCUTANEOUS ABSORPTION//PENETRATION ENHANCER//PENETRATION ENHANCERS |
| 9 | 0.0000071652 | CHAIN COPOLYMERIZATION//INHIBITORS OF AGGREGATION//INVIVO CULTURE |
| 10 | 0.0000070675 | ORGAN POLYMER MAT CHEM//BASE CATALYSED HYDROLYSIS//LINDEMANN MECHANISM |